Close
Achema middle east
swop processing & packaging

US Biotech Affinivax To Be Bought By GSK For $3.3 billion

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

WALTHAM, Mass. (October 16, 2025) – Thermo Fisher Scientific Inc....

Why Anti-Wrinkle Injections Are Gaining Popularity in Ireland

Over the past decade, Ireland has seen a significant...

Driving Excellence in Pharmaceutical Production with Advanced Pharmaceutical Cooling Systems

Introduction In pharmaceutical manufacturing, every degree matters. Process cooling is...

AstraZeneca and Daiichi Report Datroway Efficacy for TNBC

Datroway, a cancer drug developed by AstraZeneca and Daiichi...

In a deal worth up to $3.3 billion, GlaxoSmithKline (GSK) has reached a formal agreement to buy 100% of the outstanding shares of Affinivax, a clinical-stage biopharmaceutical company based in the United States. GSK will make an initial payment of $2.1 billion when the purchase closes. The company will pay $0.6 billion in two instalments if specific paediatric clinical development objectives are met in the future.

As part of the deal, GSK will receive access to the 24-valent pneumococcal vaccine candidate as well as the Multiple Antigen Presenting System (MAPS) technology. Compared to previous conjugation technologies, Affinivax’s MAPS technology allows for more valency.

This allows for broader coverage against common pneumococcal serotypes, potentially increasing immunogenicity over existing vaccinations. AFX3772, the company’s most advanced vaccine candidate, contains 24 pneumococcal polysaccharides and two conserved pneumococcal proteins, compared to up to 20 serotypes in already authorised vaccines.

The vaccine was well tolerated and provided good immune responses compared to the existing standard of care, as per findings from Phase I and II clinical studies in adults. The vaccine’s Phase III trial is slated to begin soon, while the vaccine’s Phase I/II clinical trials in paediatric participants are expected to begin later this year.

A potential pneumococcal vaccine with 30-plus valents is now in the pre-clinical stage of development. The proposed acquisition significantly enhances the vaccine R&D pipeline, allows access to a new, possibly disruptive technology, and broadens GSK’s current scientific footprint in the Boston area, said Dr. Hal Barron, GSK’s R&D chief scientific officer and president.

They are excited to collaborate with Affinivax’s many bright employees to use their industry-leading development, production, and commercialization capabilities to bring this intriguing new technology to those who need it. The transaction will be treated as a business combination, according to the company. It is expected to close in Q3 of this year, subject to the requisite closing conditions. The latest move comes after China’s National Medical Products Administration (NMPA) authorised GSK’s Cervarix two-dose vaccine schedule for girls aged 9 to 14 for cervical cancer prevention.

Latest stories

Related stories

Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

WALTHAM, Mass. (October 16, 2025) – Thermo Fisher Scientific Inc....

Why Anti-Wrinkle Injections Are Gaining Popularity in Ireland

Over the past decade, Ireland has seen a significant...

Driving Excellence in Pharmaceutical Production with Advanced Pharmaceutical Cooling Systems

Introduction In pharmaceutical manufacturing, every degree matters. Process cooling is...

AstraZeneca and Daiichi Report Datroway Efficacy for TNBC

Datroway, a cancer drug developed by AstraZeneca and Daiichi...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »